Qu Biologics enrolls the first patient in new Phase 2 Crohn’s Disease clinical trial
25 juil. 2018 12h53 HE
|
Qu Biologics
VANCOUVER, British Columbia, July 25, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Response to Novel Immune Therapy for Ulcerative Colitis Associated with Genetic and Immune Biomarkers
03 oct. 2017 12h16 HE
|
Qu Biologics
VANCOUVER, British Columbia , Oct. 03, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...